About phyton

This author has not yet filled in any details.
So far phyton has created 11 blog entries.

Phyton Biotech Wins Grant to Develop New Approaches to Manufacturing Artemisinin

By |2018-12-11T20:08:14+00:00November 29th, 2017|

Phyton Biotech Wins Grant to Develop New Approaches to Manufacturing Artemisinin Bill & Melinda Gates Foundation Invests in R&D Pilot for Anti-Malarial Active Pharmaceutical Ingredients AHRENSBURG, Germany, November 29, 2017 – Phyton Biotech today announced that it has received a $400,000 grant from the Bill & [...]

Phyton Biotech showcased plant cell fermentation at CPhI Worldwide

By |2019-01-07T06:25:57+00:00November 11th, 2017|

Phyton Biotech showcased plant cell fermentation at CPhI Worldwide NOVEMBER 9, 2017 This October, Phyton Biotech attended CPhI Worldwide to exhibit its capabilities and the wide range of applications for the company’s proprietary Plant Cell Fermentation Technology (PCF®). CPhI Worldwide is the largest pharmaceutical industry trade [...]

Case Study: Green Chemistry

By |2019-01-07T06:31:10+00:00October 17th, 2017|

Case Study: Green Chemistry Phyton Biotech develops and applies sustainable “green technology” manufacturing solutions for phytochemicals through its award-winning and proprietary Plant Cell Fermentation (PCF®) process. The impact of this revolutionary technology is exemplified by Phyton’s environmentally responsible paclitaxel manufacturing process. Summary of Problem: [...]

Case Study: Green Chemistry

By |2019-01-07T06:34:22+00:00October 7th, 2017|

Taxol® (manufactured by Bristol-Myers Squibb) is an important drug used to treat many types of solid tumor cancers and Kaposi’s sarcoma. It is on the World Health Organization’s List of Essential Medicines, the most needed medicines in a health care system.

Phyton Biotech Achieves Manufacturing Milestone with Thapsigargin, the Active Agent in Mipsagargin

By |2019-01-07T06:39:22+00:00August 22nd, 2016|

Phyton Biotech Achieves Manufacturing Milestone with Thapsigargin, the Active Agent in Mipsagargin AHRENSBURG, Germany--(BUSINESS WIRE)--Phyton Biotech today announced that it has achieved a major milestone in connection with the manufacture of thapsigargin, an inhibitor derived from the Thapsia plant that is the active agent for the investigational [...]

Patent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO)

By |2019-01-07T06:44:32+00:00July 13th, 2015|

Patent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO) Production of Thapsigargins by Thapsia Cell Suspension Culture" Filed by Phyton Biotech SAN ANTONIO, TX--(Marketwired - Jul 13, 2015) - GenSpera, Inc. (OTCQB: GNSZ) today announced that its strategic partner Phyton [...]

Phyton Biotech Receives CEP for Paclitaxel API Produced by Plant Cell Fermentation

By |2017-10-07T00:11:50+00:00July 17th, 2012|

Phyton Biotech Receives CEP for Paclitaxel API Produced by Plant Cell Fermentation VANCOUVER, British Columbia--Phyton Biotech, a global supplier of high-quality paclitaxel and docetaxel API, has been granted a Certificate of suitability to European Pharmacopeia (CEP) by the European Directorate for the Quality of Medicines and HealthCare (EDQM) [...]